Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-RO0467
Host Cell : CHO-K1 Size : >1x106 frozen cells/vial
| Cat. No. | CSC-RO0467 |
| Description | This cell line is derived from CHO-K1 and is engineered to stably overexpress Mouse MSLN. |
| Target Gene | MSLN |
| Gene Species | Mus musculus (Mouse) |
| Host Cell | CHO-K1 |
| Host Cell Species | Cricetulus griseus (Chinese hamster) |
| Applications |
1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation |
| Size | >1x106 frozen cells/vial |
| Stability | Validated for at least 10 passages |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
| Gene Name | Msln mesothelin [ Mus musculus ] |
| Gene Symbol | Msln |
| Synonyms | MPF |
| Gene Description | mesothelin |
| Gene ID | 56047 |
| Uni Prot ID | Q61468 |
| m RNA Refseq | NM_018857.1 |
| Protein Refseq | NP_061345.1 |
| Chromosome Location | 17 A3.3; 17 |
| Function | protein binding; |
The Mesothelin (MSLN) gene encodes for a cell surface glycoprotein primarily expressed in mesothelial cells. It has gained significant attention due to its overexpression in various cancers, including mesothelioma, ovarian cancer, and pancreatic cancer. Research on MSLN has contributed extensively to understanding its role in tumor progression, metastasis, and as a potential therapeutic target.
The development of Mouse MSLN Stable Cell Line - CHO-K1 involved the integration of MSLN gene into Chinese Hamster Ovary (CHO) cells, leading to a stable expression of MSLN. This cell line serves as a valuable tool for studying MSLN function, cellular interactions, and therapeutic interventions in cancer research. Its establishment has facilitated in vitro experiments elucidating MSLN-related mechanisms and has provided a platform for preclinical studies of novel anti-cancer therapies.
The Mouse MSLN Stable Cell Line - CHO-K1 has been pivotal in advancing our understanding of MSLN biology and its implications in cancer pathogenesis. Its development marks a significant milestone in the field, offering researchers a reliable model system to explore MSLN-associated pathways and develop targeted therapies.
Researchers have developed a novel anti-mesothelin antibody for potential immunotherapy applications in pancreatic cancer. Utilizing the MSLN Stable Cell Line - CHO-K1, researchers confirmed mesothelin overexpression and tested the binding specificity of the anti-MSLN antibody. Through Western blotting, they verified mesothelin expression in the established cell lines CHO-K1-MSLN and PANC-1-MSLN. Additionally, they screened fully human anti-MSLN antibodies using phage display technology and assessed their binding specificity on MSLN-expressing cells. The results demonstrated that the developed antibodies, P1A6E and P3F2, exhibited significantly higher binding affinity compared to SS1 and C10 antibodies. Furthermore, Biacore Surface Plasmon Resonance analysis confirmed the high affinity of the antibodies to mesothelin. These findings suggest the potential utility of anti-mesothelin antibodies for targeted immunotherapy in pancreatic cancer treatment.
Figure 1. Researchers investigated the binding properties of anti-mesothelin antibody and CAR constructs on primary human T cells using MSLN Stable Cell Line - CHO-K1. They analyzed mesothelin expression, antibody binding specificity, and CAR expression efficiency. (Jiang H, et al., 2017)
1. Tumor targeting: Utilize Mouse MSLN Stable Cell Line - CHO-K1 to study targeted therapies against mesothelin-expressing tumors, such as mesothelioma, ovarian, and pancreatic cancers.
2. Drug screening: Assess the efficacy of novel anticancer drugs by evaluating their impact on cell viability and proliferation in Mouse MSLN Stable Cell Line - CHO-K1.
3. Immunotherapy development: Investigate immune checkpoint inhibitors and monoclonal antibodies targeting mesothelin using Mouse MSLN Stable Cell Line - CHO-K1.
4. Gene expression studies: Analyze the regulatory mechanisms and downstream effects of mesothelin expression by manipulating gene expression in Mouse MSLN Stable Cell Line - CHO-K1.
5. Nanoparticle delivery: Explore the potential of nanoparticles for targeted drug delivery to mesothelin-expressing tumors using Mouse MSLN Stable Cell Line - CHO-K1 as an in vitro model.
A: CHO-K1 cells were likely selected for their robust growth and protein expression capabilities, allowing for efficient expression of Cd47 and investigation of its role in immune regulation and cancer biology.
A: Stability and expression were likely assessed through methods such as flow cytometry, immunoblotting, or functional assays measuring Cd47-mediated signaling or interactions with its ligands, with continuous selection pressure applied.
A: Characterization may involve analysis of Cd47 membrane localization, interaction with SIRPα, downstream signaling pathways, and functional implications in macrophage phagocytosis, inflammation, or cancer immune evasion.
A: Quality control likely included confirmation of Cd47 expression levels, validation of its functional activity and specificity, assessment of off-target effects, and validation of phenotypic changes associated with Cd47 modulation.
A: Comparative analysis with primary immune cells or in vivo models helps validate the relevance of Cd47 expression in immune checkpoints, tumor immune evasion, and its potential as a target for cancer immunotherapy, guiding the development of Cd47-targeted therapeutics.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Exceptional reliability! The Mouse MSLN Stable Cell Line in CHO-K1 cells provides consistent MSLN expression, ensuring dependable results in my cancer research.
Simplifying complex studies! With stable MSLN expression, I can explore tumor progression mechanisms with confidence, streamlining my experiments and accelerating discoveries.
Impressive performance! This cell line exceeds expectations, offering a reliable platform for investigating MSLN-targeted therapies and tumor immunotherapy.
Streamlining my workflow! Its stable expression simplifies data interpretation and enhances the efficiency of my assays, enabling precise analysis.
A valuable tool! The Mouse MSLN Stable Cell Line has revolutionized my research, providing invaluable insights into MSLN-mediated tumor biology and potential therapeutic strategies.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.